学会及びパブリケーション

A phase 2 study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors BGB-21447, a BCL-2 inhibitor, shows high potential in BCL-2 overexpressing B cell non-Hodgkin lymphomas (NHL) cancers in preclinical studies BGB-21447, a next-generation Bcl-2 inhibitor, demonstrates superior potency and overcomes venetoclax resistance in preclinical models of hematologic malignancies BGB-58067, a brain-penetrative MTA-cooperative PRMT5 inhibitor, demonstrates promising anti-tumor activity and favorable selectivity in tumors with MTAP-deletion Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC) Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors Sonrotoclax (BGB-11417), a selective BCL-2 inhibitor, demonstrates better efficacy than venetoclax and lisaftoclax (APG-2575) in hematological cancer cells, xenografts, and human bloods

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors A phase 2 study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) BGB-21447, a next generation Bcl-2 inhibitor, shows high potential in Bcl-2 overexpressing non-Hodgkin lymphomas (NHL) cancers in preclinical studies BGB-21447, a next-generation BCL-2 inhibitor, demonstrates superior potency to venetoclax and overcomes diverse BCL-2 mutations in preclinical models of hematologic malignancies BGB-58067, a brain-penetrative MTA-cooperative PRMT5 inhibitor, demonstrates promising anti-tumor activities and favorable selectivity in tumors with MTAP-deletion Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC) Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors Sonrotoclax (BGB-11417), a selective Bcl-2 inhibitor, demonstrates better efficacy than venetoclax (Ven) and lisaftoclax (APG-2575) in hematological cancer cells, xenografts, and human bloods

Electronic Patient-Reported Cardiovascular-Related and Clinically Relevant Symptoms in Patients Diagnosed With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Treated With a Second-Generation Bruton Tyrosine Kinase Inhibitor Real-World Chronic Lymphocytic Leukemia–Specific Biomarker Testing Patterns and Frontline Treatment Patterns in Community Oncology Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: an Electronic Health Record Study Switching to Zanubrutinib in Patients Diagnosed With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Previously Treated With Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting Treatment Patterns and Healthcare Resource Utilization in Advanced Esophageal Cancer Across Racial and Ethnic Groups in the Immunotherapy Era: A Retrospective Claims Data Analysis in the United States Treatment Patterns and Outcomes Among Patients Treated With Next-Generation Covalent Bruton Tyrosine Kinase Inhibitors (cBTKi) in Chronic Lymphocytic Leukemia (CLL) at the University of California San Francisco Health (UCSF) System

Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in community oncology patients with CLL/small lymphocytic lymphoma (SLL): an electronic health record study

Zanubrutinib + Obinutuzumab Vs Obinutuzumab in Relapsed/Refractory Follicular Lymphoma: Final Analysis of ROSEWOOD

Number Needed to Treat to Avoid Progression or Death in Relapsed/Refractory Chronic Lymphocytic Leukemia Patient Preferences and Factors Affecting Patient Treatment Decisions for Chronic Lymphocytic Leukemia in Japan

JSMO 2026 Abstract: ALPINE LTE1 Zanu Patients

Evaluating Patient Preferences for Chronic Lymphocytic Leukemia in Korea: A Discrete Choice Experiment

Patient Preferences For Chronic Lymphocytic Leukemia (CLL) In Korea: A Discrete Choice Experiment

A Comparison of Tislelizumab Plus Chemotherapy vs Programmed Cell Death Protein-1 (PD-1) Inhibitor Monotherapy in First‑Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% PD-(L)1 inhibitors for first-line treatment of extensive-stage small-cell lung cancer in Asian and non-Asian patients: a meta-analysis RATIONALE-304: Baseline Tumor Genomic Alterations According to Programmed Death-Ligand 1 Subgroups in Non-Squamous Non-Small Cell Lung Cancer Treated With First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone RATIONALE-315: Association of Residual Viable Tumor and Nodal Status With Survival Benefit for Patients With Resectable Non-Small Cell Lung Cancer Treated With Perioperative Tislelizumab

PD-(L)1 inhibitors for first-line treatment of ES-SCLC in Asian and non-Asian patients: a meta-analysis RATIONALE-304: baseline tumour genomic alterations according to programmed death-ligand 1 (PD-L1) subgroups in nonsquamous non-small cell lung cancer (nsq- NSCLC) treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (Pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS) comparison of tislelizumab (TIS) plus chemotherapy (CT) vs programmed cell death protein-1 (PD-1) inhibitor monotherapy in first-line (1L) non-squamous (nsq) non-small cell lung cancer (nsclc) patients (pts) with programmed cell-death ligand 1 (PD-L1) ≥50%

Outcomes During BTKi Treatment for Chronic Lymphocytic Leukemia: Insights From Remote Therapeutic Monitoring Real-World Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treatment Patterns at Florida Cancer Specialists & Research Institute Among Patients Receiving Zanubrutinib Immediately Following Prior BTKi Therapy Real-World Treatment Patterns and Patient Characteristics of Venetoclax Combination Time-Limited Therapy for Chronic Lymphocytic Leukemia Treatment Patterns and Outcomes Among Patients Treated With Next-Generation Covalent Bruton Tyrosine Kinase Inhibitors (cBTKi) in Chronic Lymphocytic Leukemia (CLL) at the University of California San Francisco Health (UCSF) System